Avata Biosciences Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

Avata Biosciences General Information

Description

Operator of a biopharmaceutical company intended to improve the lives of patients living with neurological disease. The company specializes in developing technology that produces cannabinoid APIs, creates hydrophilic conical structures with space to internalize cannabinoid molecules, and utilizes synthetically derived cannabinoids to focus on neuroscience drug discovery with assets in clinical development and benefits from the experience gained in cannabinoid drug development, enabling patients with neuroscience prescription medicines to have assistance with serious diseases.

Contact Information

Formerly Known As
Sapient Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6 Stratton Street
  • Mayfair
  • London W1J 8LD
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 6 Stratton Street
  • Mayfair
  • London W1J 8LD
  • England, United Kingdom

Avata Biosciences Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avata Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private Completed Clinical Trials - Phase 1
3. Early Stage VC Completed Clinical Trials - Phase 1
2. Seed Round 07-Mar-2024 $5.67M $5.9M Completed Clinical Trials - Phase 1
1. Angel (individual) 14-Nov-2022 $229K $229K Completed Clinical Trials - Phase 1
To view Avata Biosciences’s complete valuation and funding history, request access »

Avata Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 31,667 $0.001264 $7.98 $7.98 1x $7.98 19.25%
To view Avata Biosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Avata Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to improve the lives of patients living with neurological disease. The
Drug Discovery
London, United Kingdom
12 As of 2026

Burnaby, Canada
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Avata Biosciences Competitors (4)

One of Avata Biosciences’s 4 competitors is Xenon Pharmaceuticals, a Formerly VC-backed company based in Burnaby, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xenon Pharmaceuticals Formerly VC-backed Burnaby, Canada
Biohaven Formerly VC-backed New Haven, CT
SK Biopharmaceuticals Corporation Seongnam, South Korea
Jazz Pharmaceuticals Formerly VC-backed Dublin, Ireland
To view Avata Biosciences’s complete competitors history, request access »

Avata Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avata Biosciences Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Harwood Private Capital Mezzanine Minority
5 Horizons Capital Venture Capital Minority
To view Avata Biosciences’s complete investors history, request access »

Avata Biosciences FAQs

  • When was Avata Biosciences founded?

    Avata Biosciences was founded in 2022.

  • Where is Avata Biosciences headquartered?

    Avata Biosciences is headquartered in London, United Kingdom.

  • What is the size of Avata Biosciences?

    Avata Biosciences has 12 total employees.

  • What industry is Avata Biosciences in?

    Avata Biosciences’s primary industry is Drug Discovery.

  • Is Avata Biosciences a private or public company?

    Avata Biosciences is a Private company.

  • What is Avata Biosciences’s current revenue?

    The current revenue for Avata Biosciences is .

  • How much funding has Avata Biosciences raised over time?

    Avata Biosciences has raised $45.9M.

  • Who are Avata Biosciences’s investors?

    Harwood Private Capital and 5 Horizons Capital have invested in Avata Biosciences.

  • Who are Avata Biosciences’s competitors?

    Xenon Pharmaceuticals, Biohaven, SK Biopharmaceuticals, and Jazz Pharmaceuticals are competitors of Avata Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process